Other News |
Press Releases
HealtTalk article: “Ultimovacs med lovende 2-års overlevelsesdata: 80 prosent av pasientene lever etter 2 år”
“Ultimovacs har gått ut med 2-års overlevelsesdata fra sin fase-1 studie der nydiagnostiserte pasienter med metastatisk føflekkreft fikk kreftvaksinen UV1 […]
BioStock article on the Positive phase I data for Ultimovacs
“Biotech company Ultimovacs continues to strengthen the clinical evidence for its universal cancer vaccine UV1. On Wednesday morning the company […]
Two Key Appointments to the Management Team as the Operations Advances
Ultimovacs ASA today announced two senior appointments to its management team: Orla Mc Callion as Head of Regulatory Affairs & […]
Biostock article on the TENDU trial and the TET-platform
“Ultimovacs’ TENDU trial is a clinical phase I study aimed at testing the company’s TET platform for cancer vaccine development […]
Finansavisen – Topline results
Read the Finansavisen article (in Norwegian) here
Open position as Head of Investor Relations and Communication
Ultimovacs is searching for Head of Investor Relations and Communication. For more information, please see here
Presentation at LifeSci Nordic Biotech Summit Tuesday 29 June 2021
CEO of Ultimovacs, Carlos de Sousa, will hold a company presentation at LifeSci Nordic Biotech Summit on Tuesday 29 June […]
Biostock article on Ultimovacs’ clinical data presented at ASCO
“This year’s virtual ASCO conference featured Ultimovacs’ recently released phase I data showing that cancer vaccine UV1 boosts the effects […]
ASCO data – HealthTalk interview with CMO Jens Bjørheim
See the whole interview here